Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany
- PMID: 36763757
- DOI: 10.1093/bjd/ljac070
Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany
Conflict of interest statement
Conflicts of interest: J.S. is coprincipal investigator of TREATgermany and reports institutional grants for investigator-initiated research from the German GBA, the BMG, BMBF, EU, Federal State of Saxony, Novartis, Sanofi, ALK and Pfizer. He participated in advisory board meetings as a paid consultant for Sanofi, Lilly and ALK. K.S. received honoraria as an investigator, speaker’s honoraria and grants, and has been an advisor for the following companies: AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Eli-Lilly, Galderma, Janssen, LEO Pharma, Merck Serono, Morphosys, Novartis, Pfizer, Regeneron, Sanofi and UCB Pharma. L.H. is a research associate of TREATgermany, which is an academic, investigator-initiated clinical registry that is financially supported by AbbVie GmbH & Co. KG, Galderma S. A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc. and Sanofi-Aventis Deutschland GmbH. S.A. has received lecture and/or consultancy fees from Novartis, LEO Pharma, Amgen, Lilly, Sanofi, Beiersdorf, Janssen, UCB and AbbVie. E.W. received consultancy fees from Sanofi/Genzyme and has participated in clinical trials for Galderma Ltd and TREVI Ltd.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
